Cargando…

Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors

Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder in reproductive-age women. PCOS is characterized by androgen excess, oligo/anovulation, and polycystic appearance of the ovaries. Women with PCOS have an increased prevalence of multiple cardiovascular risk factors such as insuli...

Descripción completa

Detalles Bibliográficos
Autores principales: Pruett, Jacob E., Romero, Damian G., Yanes Cardozo, Licy L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974663/
https://www.ncbi.nlm.nih.gov/pubmed/36875461
http://dx.doi.org/10.3389/fendo.2023.951099
_version_ 1784898760836382720
author Pruett, Jacob E.
Romero, Damian G.
Yanes Cardozo, Licy L.
author_facet Pruett, Jacob E.
Romero, Damian G.
Yanes Cardozo, Licy L.
author_sort Pruett, Jacob E.
collection PubMed
description Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder in reproductive-age women. PCOS is characterized by androgen excess, oligo/anovulation, and polycystic appearance of the ovaries. Women with PCOS have an increased prevalence of multiple cardiovascular risk factors such as insulin resistance, hypertension, renal injury, and obesity. Unfortunately, there is a lack of effective, evidence-based pharmacotherapeutics to target these cardiometabolic complications. Sodium-glucose cotransporter-2 (SGLT2) inhibitors provide cardiovascular protection in patients with and without type 2 diabetes mellitus. Although the exact mechanisms of how SGLT2 inhibitors confer cardiovascular protection remains unclear, numerous mechanistic hypotheses for this protection include modulation of the renin-angiotensin system and/or the sympathetic nervous system and improvement in mitochondrial function. Data from recent clinical trials and basic research show a potential role for SGLT2 inhibitors in treating obesity-associated cardiometabolic complications in PCOS. This narrative review discusses the mechanisms of the beneficial effect of SGLT2 inhibitors in cardiometabolic diseases in PCOS.
format Online
Article
Text
id pubmed-9974663
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99746632023-03-02 Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors Pruett, Jacob E. Romero, Damian G. Yanes Cardozo, Licy L. Front Endocrinol (Lausanne) Endocrinology Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder in reproductive-age women. PCOS is characterized by androgen excess, oligo/anovulation, and polycystic appearance of the ovaries. Women with PCOS have an increased prevalence of multiple cardiovascular risk factors such as insulin resistance, hypertension, renal injury, and obesity. Unfortunately, there is a lack of effective, evidence-based pharmacotherapeutics to target these cardiometabolic complications. Sodium-glucose cotransporter-2 (SGLT2) inhibitors provide cardiovascular protection in patients with and without type 2 diabetes mellitus. Although the exact mechanisms of how SGLT2 inhibitors confer cardiovascular protection remains unclear, numerous mechanistic hypotheses for this protection include modulation of the renin-angiotensin system and/or the sympathetic nervous system and improvement in mitochondrial function. Data from recent clinical trials and basic research show a potential role for SGLT2 inhibitors in treating obesity-associated cardiometabolic complications in PCOS. This narrative review discusses the mechanisms of the beneficial effect of SGLT2 inhibitors in cardiometabolic diseases in PCOS. Frontiers Media S.A. 2023-02-15 /pmc/articles/PMC9974663/ /pubmed/36875461 http://dx.doi.org/10.3389/fendo.2023.951099 Text en Copyright © 2023 Pruett, Romero and Yanes Cardozo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Pruett, Jacob E.
Romero, Damian G.
Yanes Cardozo, Licy L.
Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors
title Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors
title_full Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors
title_fullStr Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors
title_full_unstemmed Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors
title_short Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors
title_sort obesity-associated cardiometabolic complications in polycystic ovary syndrome: the potential role of sodium-glucose cotransporter-2 inhibitors
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974663/
https://www.ncbi.nlm.nih.gov/pubmed/36875461
http://dx.doi.org/10.3389/fendo.2023.951099
work_keys_str_mv AT pruettjacobe obesityassociatedcardiometaboliccomplicationsinpolycysticovarysyndromethepotentialroleofsodiumglucosecotransporter2inhibitors
AT romerodamiang obesityassociatedcardiometaboliccomplicationsinpolycysticovarysyndromethepotentialroleofsodiumglucosecotransporter2inhibitors
AT yanescardozolicyl obesityassociatedcardiometaboliccomplicationsinpolycysticovarysyndromethepotentialroleofsodiumglucosecotransporter2inhibitors